The BioFire BCID2 Panel tests for 43 targets associated with bloodstream infections, including gram-negative bacteria, gram-positive bacteria, yeast, and 10 antimicrobial resistance genes—all with one test and with results available in about an hour from positive blood culture.

The BioFire BCID2 Panel features broadened inclusivity for Enterobacterales, new assays for fungal and anaerobic pathogens, and additional identification of coagulase negative Staphylococcus species. The BioFire BCID2 Panel menu includes seven additional resistance genes, including carbapenemases and colistin resistance genes. An MREJ assay allows for more specific MRSA identification.

1. Simple: 2 minutes hands-on time
2. Fast: Turnaround time of about 60 minutes
3. Comprehensive: Simultaneously tests for 43 targets and identifies pathogens in more than 9 out of 10 antimicrobial resistance genes and emerging pathogens like C.auris and S.maltophilia
4. Accurate: The average positive agreement rate (or sensitivity) across all pathogens on the BCID2 panel is 99%, and the negative agreement rate (or specificity) is 99.8%